Search
anakinra (Kineret)
Indications:
1) treatment of rheumatoid arthritis (FDA approved 2001)*
2) adult-onset Still's disease (off-label) [4]
3) cryopyrin-associated periodic syndrome [4]
4) acute gouty arthritis (off-label) [4,5,6]
* rarely used for rheumatoid arthritis since other biologic DMARDs superior [4]
Contraindications:
- concurrent use of other biologic agent (TNF inhibitor, rituximab, abatacept)
Pregnancy category: B
Dosage:
- 1-2 mg/kg SC in combination with methotrexate [3]
Monitor:
- complete blood count (CBC) at baseline & every 3 months [4]
Adverse effects:
- reversible neutropenia [4]
Laboratory:
- anakinra in serum/plasma
Mechanism of action:
- recombinant interleukin-1 beta inhibitor [4]
- pharmaceutical form of IL-1 receptor antagonist protein
Notes: Manufacturer: Amgen
Management:
- whenever possible bring patients up to date on vaccinations prior to initiating biologic immunosuppressive agent [4]
Interactions
drug adverse effects of immunosuppressive agents
monitor with immunosuppressive agents
Related
interleukin-1; lymphocyte-activating factor (IL1)
General
biologic immunosuppressive agent (biologic agent, biologic immune modulator)
interleukin-1 receptor antagonist protein; IL-1ra; IL-1RN; IRAP; IL1 inhibitor; ICIL-1RA (IL1RN, IL1F3, IL1RA)
References
- Prescriber's Letter 9(2):S1 2002
- Prescriber's Letter 9(3):13 2002
- Journal Watch 22(9):70, 2002
Dayer J-M & Bresniban R,
Targeting interleukin-1 in the treatment of rheumatoid arthritis.
Arthritis Rheum 46:574, 2002
PMID: 11920390
- Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18, 19.
American College of Physicians, Philadelphia 2012, 2015, 2018, 2022.
- Thueringer JT, Doll NK, Gertner E.
Anakinra for the treatment of acute severe gout in critically
ill patients.
Semin Arthritis Rheum. 2015 Aug;45(1):81-5. Epub 2015 Feb 20.
PMID: 25795473
- Liew JW, Gardner GC.
Use of anakinra in hospitalized patients with crystal-associated
arthritis.
J Rheumatol 2019 Oct; 46:1345
PMID: 30647192
http://www.jrheum.org/content/46/10/1345